Schizophrenia is considered an important illness with altered perception and thought, hallucinations or delusions, and behaviour that interferes with the patient’s work and social relationships. In a majority of cases, it is dealt with via neuroleptics; they primarily have an effect in blocking dopamine, and their side effects mean that they barely help in the improvement of memory and attention abilities.
The main body of the article discusses those studies finding that the number of a particular kind of muscarinic receptor called the “M1 receptor” had decreased in patients with a history of a diagnosis of schizophrenia. This data should make a great amount of sense for determining the relevance and importance of cholinergic signalling, or muscarinic signalling, in schizophrenia and finding effective new treatment strategies.
Read More: Genetic Insights into Schizophrenia from Rare Variants
Role of Muscarinic Receptors in Schizophrenia
The principal thesis is that the muscarinic M1 receptor in the brain is downregulated in subjects with schizophrenia. It is hypothesised that muscarinic receptors involved centrally in afferent limbic circuits may be critically involved in attention processes, learning and memory processes, and cognitive flexibility abnormalities in the disease. M1 receptors are particularly found in the hippocampus and the cortex, brain areas where these functions are located.
Earlier post-mortem studies revealed reduced M1 receptor expression in schizophrenia; however, these investigations were limited in their capacity to assess cause-effect relationships and the broader implications of these expression abnormalities in living patients. This study employed modern neuroimaging approaches to visualise M1 receptors in vivo and associate them with disease state and clinical symptoms.
At the level of mental activity, we can formulate the following hypothesis: schizophrenia is associated with dysregulation of the cholinergic system, in particular, D1 receptor subunits, which underlies some of the cognitive and negative symptoms of the disease and can be a target for developing new therapy.
Read More: Cognitive Challenges in People with Schizophrenia and Personality Disorders
Experimental Design (Between-Group Participant Design)
In the research process, the authors used patients with a diagnosis of schizophrenia and a control group of healthy patients. All participants were subjected to positron emission tomography. However, the study used an innovative PET radioactively labelled drug for detecting M1 muscarinic receptors. This technique enabled the researchers to see the number of these receptors in various parts of the brain of living people. Previously existing methods only permitted the estimation of receptor quantity in brain tissue samples obtained from deceased patients.
The main goals of the study were to establish the levels of M1 receptors in several areas of the brain among the participants diagnosed with schizophrenia, compare these levels to the results obtained from healthy control subjects, and determine whether there is a connection between the amount of M1 receptors and the manifestation of positive and negative symptoms plus cognitive deficits. The research team consisted of neuroscience and psychiatric scholars, who are typically involved in such PET studies. It is likely that the patients were subjected to clinical interviews, symptom rating assessments, and cognitive performance tests to evaluate the relationship between their cognitive functions and the observed biological patterns.
Read More: Brain Damage and Neural Changes in Schizophrenia: How the Disorder Affects the Brain
Lack of M1 Receptor Predominant Symptom of Schizophrenia
Researchers reported that people with schizophrenia displayed lower M1 receptor binding in multiple regions of the brain. Results were not just confined to one brain region but were widespread in key areas governing complex thought and planning, as well as emotion and memory in the cortex, caudate, and hippocampus. Importantly, this confirms that the deficits are a common finding in schizophrenia, rather than an isolated observation, since a subgroup with extensive cortical M1 deficit has previously been identified.
Thus, involvement of the M1 receptor is likely to be widespread in schizophrenia, which would be expected to have a significant impact on glutamatergic neurotransmission, leading to disturbances in downstream GABAergic circuits, resulting in cognitive and information processing impairments. The behavioural and clinical relevance of these deficits is consistent with the cognitive endophenotype associated with the illness, including impaired attention, working memory, and flexible thought processes despite being on antipsychotic medication.
Read More: How Neurons Choose a Single Axon: New Research Reveals an Internal Growth Mechanism
Author’s Insights
The researchers believe that these results confirm the crucial role of muscarinic M1 receptors in the molecular mechanism of schizophrenia. They hypothesise that the disruption of the function of these receptors in various areas of the brain leads to the development of the disease. Therefore, the use of agonists of M1 (and partly M4) receptors, such as xanomeline, can significantly alleviate the symptoms of the illness, including cognitive and negative signs, as well as reduce the dependence on dopamine blockers.
In another finding, the authors mention that there is a certain degree of heterogeneity among patients diagnosed with schizophrenia since a considerable proportion of them exhibits notably reduced cortical M1 volume. They suggest that such individuals might demonstrate a preferential treatment response to muscarinic receptor agonists targeting the orthosteric site (M1/M4), which implies the necessity of personalised medicine. The authors further discuss the possibility of individualising the treatment by developing modulators of other receptor regions (i.e., allosteric sites) and posit that assessing patients’ response to the drug using PET M1 measurements or peripheral blood transcript biomarkers of cognitive endophenotypes can help predict their treatment outcome.
The researchers note that their study provides critical preclinical proof-of-concept evidence of the link between muscarinic system dysfunctions and the disorder, which has tremendous clinical relevance given the recent advancements in developing muscarinic-based therapeutics. They conclude by stating that these findings represent an essential step towards advancing the understanding of the disease and moving the research field “from theoretical formulations to therapeutic practice” by contributing to developing new treatment strategies and supporting the paradigm of schizophrenia as a biologically defined syndrome, rather than just a dopamine-related disease.
Read More: Procrastination Reconsidered: A Research-Based Classification of Nine Behavioural Types
Conclusion
The presented research provides evidence of the prevalence of muscarinic M1 receptor deficits in patients diagnosed with schizophrenia. The symptoms are applicable to the majority of patients, which can be observed through the utilisation of PET imaging. The results demonstrate the connection between these receptor abnormalities and the regions of the brain responsible for cognitive and motivational functions.
These findings help explain the presence of cognitive impairments along with negative symptoms commonly observed in the disorder despite the implementation of dopamine receptor antagonists. The main conclusion from this study is that M1 receptors are deserving of further clinical exploration. Specifically, more research is needed to establish how and whether people with deficits in M1 function would respond to different muscarinic treatments.
Overall, this line of investigation is useful, as it helps advance the development of more personalised and evidence-based treatments for mental disorders, grounded in the understanding of their biological mechanisms. Moreover, by promoting the idea that there is more to schizophrenia than positive symptoms, which was the dominant perspective at the time, this study helped lay the groundwork for the emergence of more diverse and multidimensional approaches to studying the condition, which continue to yield better treatment outcomes.
References +
- News, N. (2012). Sharp images from the living mouse brain—neuroscience news. In Neuroscience News. https://neurosciencenews.com/s
